New data, generated by Thomas Jung and colleagues, at Novartis Exploratory Development, Switzerland, have indicated that a drug known currently as AEB071 can reduce the clinical symptoms of psoriasis, a chronic, currently incurable autoimmune skin disease. In the study, healthy volunteers and patients with psoriasis were administered AEB071 by mouth. Different groups of individuals received different doses of the drug, but all doses were well tolerated with no obvious side effects.
This post is an original post by ScienceDaily: Skin Care News
